Is metformin a geroprotector? A peek into the current clinical and experimental data
Copyright © 2020 Elsevier B.V. All rights reserved..
Nowadays we observe a growing scientific interest and need to develop novel research approach that target ageing. Metformin, apart from its proven efectiveness as a glucose-lowering agent, was found to exert multidirectional effects because of its cardioprotective, anti-inflammatory and anti-cancer activity. Recently, metformin has become a subject of interest of many researchers as a promising drug with anti-ageing properties; however, its impact on clinical ageing features is still hypothetical. Nevertheless, results of cellular experiments and animal studies confirm that metformin has advantageous effects on ageing. Additionally, a number of clinical trials prove positive effects of metformin on the prevalence of age-related diseases (ARD), including cardiovascular disease or carcinoma. We have observed a significant advancement in human research since a few randomised clinical trials evaluating the impact of metformin on ageing were launched. Here, we present an investigation on anti-ageing properties of metformin, and provide the explanation of mechanisms and pathways implicated in this function. We also analyse available clinical evidence on healthspan extension, all-cause mortality and ARD. Finally, we discuss currently conducted randiomized clinical trials which aim to explore metformin potential as an anti-ageing drug in humans.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:191 |
|---|---|
| Enthalten in: |
Mechanisms of ageing and development - 191(2020) vom: 10. Okt., Seite 111350 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zajda, Agnieszka [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9100L32L2N |
|---|
| Anmerkungen: |
Date Completed 13.10.2021 Date Revised 13.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.mad.2020.111350 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314784012 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314784012 | ||
| 003 | DE-627 | ||
| 005 | 20231225153502.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.mad.2020.111350 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1049.xml |
| 035 | |a (DE-627)NLM314784012 | ||
| 035 | |a (NLM)32905803 | ||
| 035 | |a (PII)S0047-6374(20)30146-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zajda, Agnieszka |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Is metformin a geroprotector? A peek into the current clinical and experimental data |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.10.2021 | ||
| 500 | |a Date Revised 13.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier B.V. All rights reserved. | ||
| 520 | |a Nowadays we observe a growing scientific interest and need to develop novel research approach that target ageing. Metformin, apart from its proven efectiveness as a glucose-lowering agent, was found to exert multidirectional effects because of its cardioprotective, anti-inflammatory and anti-cancer activity. Recently, metformin has become a subject of interest of many researchers as a promising drug with anti-ageing properties; however, its impact on clinical ageing features is still hypothetical. Nevertheless, results of cellular experiments and animal studies confirm that metformin has advantageous effects on ageing. Additionally, a number of clinical trials prove positive effects of metformin on the prevalence of age-related diseases (ARD), including cardiovascular disease or carcinoma. We have observed a significant advancement in human research since a few randomised clinical trials evaluating the impact of metformin on ageing were launched. Here, we present an investigation on anti-ageing properties of metformin, and provide the explanation of mechanisms and pathways implicated in this function. We also analyse available clinical evidence on healthspan extension, all-cause mortality and ARD. Finally, we discuss currently conducted randiomized clinical trials which aim to explore metformin potential as an anti-ageing drug in humans | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Ageing | |
| 650 | 4 | |a Biguanides | |
| 650 | 4 | |a Geroprotector | |
| 650 | 4 | |a Metformin | |
| 650 | 4 | |a Senescence | |
| 650 | 7 | |a Metformin |2 NLM | |
| 650 | 7 | |a 9100L32L2N |2 NLM | |
| 700 | 1 | |a Huttunen, Kristiina M |e verfasserin |4 aut | |
| 700 | 1 | |a Sikora, Joanna |e verfasserin |4 aut | |
| 700 | 1 | |a Podsiedlik, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Markowicz-Piasecka, Magdalena |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Mechanisms of ageing and development |d 1973 |g 191(2020) vom: 10. Okt., Seite 111350 |w (DE-627)NLM000007528 |x 1872-6216 |7 nnns |
| 773 | 1 | 8 | |g volume:191 |g year:2020 |g day:10 |g month:10 |g pages:111350 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.mad.2020.111350 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 191 |j 2020 |b 10 |c 10 |h 111350 | ||